{"classes":[{"categories":[{"measurements":[{"comment":"Upper confidence interval value could not be calculated as the fraction of participants experiencing events was too low.","groupId":"OG000","lowerLimit":"7.6","upperLimit":"NA","value":"15.7"},{"comment":"Upper confidence interval value could not be calculated as the fraction of participants experiencing events was too low.","groupId":"OG001","lowerLimit":"13.7","upperLimit":"NA","value":"21.3"},{"comment":"Upper confidence interval value could not be calculated as the fraction of participants experiencing events was too low.","groupId":"OG002","lowerLimit":"13.10","upperLimit":"NA","value":"27.20"},{"groupId":"OG003","lowerLimit":"8.40","upperLimit":"14.50","value":"10.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"20"}],"units":"Participants"}],"description":"DOCB was defined as time in months from the first evidence of confirmed assessment of sCR, CR, VGPR, PR or MR to first confirmed disease progression, or to death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered IV melflufen at a dose of 30 mg on Day 1 of each 28-day cycle in combination with SQ bortezomib at a dose of 1.3mg/m\\^2 on Days 1, 4, 8, and 11 and dexamethasone PO at a dose of 20 mg (12 mg if the participants is ≥ 75 years of age) on Days 1, 4, 8, and 11 and 40 mg (20 mg if the participants is ≥ 75 years of age) on Day 15 and 22 of each 28-day cycle.","id":"OG000","title":"A (Melflufen+Bortezomib+Dex) 30 mg"},{"description":"Participants were administered IV melflufen at a dose of 40 mg on Day 1 of each 28-day cycle in combination with SQ bortezomib at a dose of 1.3mg/m\\^2 on Days 1, 4, 8, and 11 and dexamethasone PO at a dose of 20 mg (12 mg if the participants is ≥ 75 years of age) on Days 1, 4, 8, and 11 and 40 mg (20 mg if the participants is ≥ 75 years of age) on Day 15 and 22 of each 28-day cycle.","id":"OG001","title":"A (Melflufen+Bortezomib+Dex) 40 mg"},{"description":"Participants were administered IV melflufen at a dose of 30 mg on Day 1 of each 28-day cycle in combination with daratumumab at a dose of 16 mg/kg weekly for 8 doses, every other week for 8 doses and then once every 4 weeks. Participants were also administered dexamethasone PO at a dose of 40 mg weekly (20 mg weekly if the participants is ≥ 75 years of age).","id":"OG002","title":"B (Melflufen+Daratumumab+Dex) 30 mg"},{"description":"Participants were administered IV melflufen at a dose of 40 mg on Day 1 of each 28-day cycle in combination with daratumumab at a dose of 16 mg/kg weekly for 8 doses, every other week for 8 doses and then once every 4 weeks. Participants were also administered dexamethasone PO at a dose of 40 mg weekly (20 mg weekly if the participants is ≥ 75 years of age).","id":"OG003","title":"B (Melflufen+Daratumumab+Dex) 40 mg"}],"paramType":"MEDIAN","populationDescription":"All participants included in the Safety Analysis Set with a confirmed MR or better were included in this analysis.","reportingStatus":"POSTED","timeFrame":"Until disease progression, death or initiation of subsequent therapy (a maximum of 194.3 weeks)","title":"Duration of Clinical Benefit (DOCB)","type":"SECONDARY","unitOfMeasure":"months"}